Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MacroGenics ( (MGNX) ) has shared an announcement.
On August 13, 2025, MacroGenics announced the appointment of Eric Risser as President, Chief Executive Officer, and Director, succeeding Scott Koenig, who led the company for 24 years. Risser, previously the Chief Operating Officer, aims to focus on creating a capital-efficient biotechnology company that delivers novel therapies for cancer patients, reflecting a strategic shift in leadership and vision for the company’s future.
The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.
Spark’s Take on MGNX Stock
According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.
MacroGenics’ overall stock score is primarily influenced by its financial challenges, including profitability and liquidity issues. The technical analysis provides mixed signals, and the valuation is weakened by the negative P/E ratio. However, the recent corporate event involving the Royalty Purchase Agreement with Sagard is a positive factor, providing additional financial stability.
To see Spark’s full report on MGNX stock, click here.
More about MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary suite of next-generation antibody-based technology platforms to generate a pipeline of product candidates, engaging in strategic collaborations with global pharmaceutical and biotechnology companies.
Average Trading Volume: 1,238,844
Technical Sentiment Signal: Sell
Current Market Cap: $92.74M
Find detailed analytics on MGNX stock on TipRanks’ Stock Analysis page.